BioWorld

Sep. 27, 2002

OGS Separating Business Into Three Units To Aid Transparency

Under the direction of a new CEO, Oxford GlycoSciences plc released a plan Thursday to reduce its burn rate and improve performance by dividing its business into three separate units. (BioWorld Today) Read More

Aureon Discloses $15M Round To Develop Cancer Diagnostics

Mystery Solved By Discovery Of Defensins, CD8 Antiviral Factor, As Announced By Phone, Journal

Georgia Among States Attempting To Increase Biotech Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...